PDS Biotechnology Corp. (PDSB)
0.2884
-0.01
(-3.87%)
USD |
NASDAQ |
Sep 09, 14:06
PDS Biotechnology Enterprise Value : 15.54M for Sept. 8, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 08, 2026 | 15.54M |
| September 04, 2026 | 11.07M |
| September 03, 2026 | 11.07M |
| September 02, 2026 | 10.62M |
| September 01, 2026 | 10.18M |
| August 31, 2026 | 10.73M |
| August 28, 2026 | 10.56M |
| August 27, 2026 | 10.95M |
| August 26, 2026 | 11.25M |
| August 25, 2026 | 11.15M |
| August 24, 2026 | 10.89M |
| August 21, 2026 | 10.99M |
| August 20, 2026 | 10.45M |
| August 19, 2026 | 9.991M |
| August 18, 2026 | 10.40M |
| August 17, 2026 | 11.10M |
| August 14, 2026 | 11.66M |
| August 13, 2026 | 11.81M |
| August 12, 2026 | 12.30M |
| August 11, 2026 | 13.13M |
| August 10, 2026 | 39.65M |
| August 07, 2026 | 42.12M |
| August 06, 2026 | 40.55M |
| August 05, 2026 | 39.41M |
| August 04, 2026 | 39.03M |
| Date | Value |
|---|---|
| August 03, 2026 | 38.72M |
| July 31, 2026 | 37.14M |
| July 30, 2026 | 37.86M |
| July 29, 2026 | 36.21M |
| July 28, 2026 | 37.39M |
| July 27, 2026 | 37.50M |
| July 24, 2026 | 36.87M |
| July 23, 2026 | 37.94M |
| July 22, 2026 | 38.78M |
| July 21, 2026 | 41.27M |
| July 20, 2026 | 38.88M |
| July 17, 2026 | 39.86M |
| July 16, 2026 | 38.54M |
| July 15, 2026 | 40.49M |
| July 14, 2026 | 40.82M |
| July 13, 2026 | 40.44M |
| July 10, 2026 | 42.05M |
| July 09, 2026 | 42.79M |
| July 08, 2026 | 44.90M |
| July 07, 2026 | 45.47M |
| July 06, 2026 | 46.08M |
| July 02, 2026 | 46.47M |
| July 01, 2026 | 47.64M |
| June 30, 2026 | 48.04M |
| June 29, 2026 | 44.38M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 3.865B |
| Alnylam Pharmaceuticals, Inc. | 34.46B |
| Anika Therapeutics, Inc. | 268.42M |
| Savara, Inc. | 993.23M |
| Vericel Corp. | 1.932B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -9.751M |
| Total Expenses (Quarterly) | 9.751M |
| EPS Diluted (Quarterly) | -0.1752 |
| Earnings Yield | -222.0% |
| Normalized Earnings Yield | -222.02 |